Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 15 de 15
Filtrar
1.
J Immunother Cancer ; 8(2)2020 11.
Artigo em Inglês | MEDLINE | ID: mdl-33203665

RESUMO

BACKGROUND: Sarcomas exhibit low expression of factors related to immune response, which could explain the modest activity of PD-1 inhibitors. A potential strategy to convert a cold into an inflamed microenvironment lies on a combination therapy. As tumor angiogenesis promotes immunosuppression, we designed a phase Ib/II trial to test the double inhibition of angiogenesis (sunitinib) and PD-1/PD-L1 axis (nivolumab). METHODS: This single-arm, phase Ib/II trial enrolled adult patients with selected subtypes of sarcoma. Phase Ib established two dose levels: level 0 with sunitinib 37.5 mg daily from day 1, plus nivolumab 3 mg/kg intravenously on day 15, and then every 2 weeks; and level -1 with sunitinib 37.5 mg on the first 14 days (induction) and then 25 mg per day plus nivolumab on the same schedule. The primary endpoint was to determine the recommended dose for phase II (phase I) and the 6-month progression-free survival rate, according to Response Evaluation Criteria in Solid Tumors 1.1 (phase II). RESULTS: From May 2017 to April 2019, 68 patients were enrolled: 16 in phase Ib and 52 in phase II. The recommended dose of sunitinib for phase II was 37.5 mg as induction and then 25 mg in combination with nivolumab. After a median follow-up of 17 months (4-26), the 6-month progression-free survival rate was 48% (95% CI 41% to 55%). The most common grade 3-4 adverse events included transaminitis (17.3%) and neutropenia (11.5%). CONCLUSIONS: Sunitinib plus nivolumab is an active scheme with manageable toxicity in the treatment of selected patients with advanced soft tissue sarcoma, with almost half of patients free of progression at 6 months.Trial registration number NCT03277924.


Assuntos
Antineoplásicos Imunológicos/uso terapêutico , Nivolumabe/uso terapêutico , Sarcoma/tratamento farmacológico , Sunitinibe/uso terapêutico , Adulto , Idoso , Antineoplásicos Imunológicos/farmacologia , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Nivolumabe/farmacologia , Sunitinibe/farmacologia , Adulto Jovem
2.
Hematol Oncol ; 33(4): 151-8, 2015 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-25407794

RESUMO

The use of PET in patients with marginal zone B cell lymphoma (MZL) is controversial because of variability of fluorodeoxyglucose (FDG) avidity. We analyzed 40 PET/CT in 25 consecutive patients to compare its performance with CT at staging and as a first-line response assessment. Sensitivity of PET/CT and CT was 96 and 76%. Mean standard uptake value was 6.1, 6.9 and 3.4 (p = 0.3) in nodal, extranodal and splenic subtypes, respectively. Of 17 patients (extranodal: n = 9; nodal: n = 6; splenic subtype: n = 2) with both imaging tests available at diagnosis, 8 (47%) had more involved areas with PET/CT than with CT, 75% of which were extranodal lesions. PET/CT resulted in upstaging of five patients although treatment of only two of them was changed. Responses of 15 patients with post-treatment PET/CT were the following: 9 negative and 6 positive of which 3 were isolated residual lesions. Progression was documented in two of these three patients. Response was also assessed by CT in 11 patients. Discrepancies were found in three: Two were in complete remission by CT while PET/CT detected localized residual disease; another patient was in partial remission by CT, whereas PET/CT showed only one positive lesion. Two of these three patients relapsed. Patients with negative post-treatment PET/CT did not relapse. With a median follow-up of 50 months (10-152 months), 3-year overall survival was 100 and 80% for patients with negative and positive post-treatment PET/CT (p = 0.2). Three-year disease-free survival was 86%; the negative predictive value (NPV) was 100%, and the positive predictive value (PPV) was 83.3%. Although a larger number of patients will be required to further confirm these data, we can conclude that PET/CT is a useful imaging tool for both staging and response assessment in patients with nodal and extranodal MZL as a result of its high sensitivity, NPV and PPV.


Assuntos
Fluordesoxiglucose F18/uso terapêutico , Linfoma de Zona Marginal Tipo Células B/diagnóstico por imagem , Tomografia por Emissão de Pósitrons/métodos , Tomografia Computadorizada por Raios X/métodos , Adulto , Idoso , Idoso de 80 Anos ou mais , Intervalo Livre de Doença , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos
3.
Eur J Haematol ; 94(1): 23-30, 2015 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-24520874

RESUMO

UNLABELLED: Burkitt lymphoma (BL) is highly FDG-avid even though its usefulness in the management of these patients is still controversial. AIM: We analyzed the role of positron emission tomography/computerized tomography (PET/CT) in staging newly diagnosed patients with BL and evaluating disease after first-line chemotherapy. METHODS: Fifty-two PET/CTs were performed in 32 patients (20 at diagnosis, 27 after treatment, five to monitor residual disease). Involved areas were retrospectively compared with those observed in contrast-enhanced CT. RESULTS: Discrepancies were found in 64.7% of patients for whom results of both tests at diagnosis were available (n = 17), most of them involving extranodal sites. Regarding response assessment, discrepancies were observed in 38% of patients with both tests (5/13): residual masses detected by CT with negative PET/CT. Of 27 patients with post-treatment PET/CT, 22 were in complete remission whereas one true-positive and four false-positive lesions (two nodal and two extranodal) were detected. With a median follow-up of 27 months, 22 patients with negative PET/CT did not relapse. Thus, negative predictive value (NPV) was 100%. With respect to positive predictive value (PPV), one of five patients with positive assays after treatment died due to progression while the remaining four had false-positive lesions. Nevertheless, for these four patients, mean SUVmax at nodal sites was 4.1 vs. 14.9 at diagnosis, while mean SUVmax at extranodal sites was 3.8 vs. 12.1. Thus, with a cutoff value for SUVmax < 66% of that observed at diagnosis, PPV was also 100%. CONCLUSION: More accurate staging can be achieved using PET/CT. NPV reaches 100%, and using a ΔSUV < 66%, a high PPV is also observed.


Assuntos
Linfoma de Burkitt/diagnóstico , Fluordesoxiglucose F18 , Tomografia por Emissão de Pósitrons , Tomografia Computadorizada por Raios X , Adolescente , Adulto , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Linfoma de Burkitt/tratamento farmacológico , Linfoma de Burkitt/mortalidade , Criança , Pré-Escolar , Gerenciamento Clínico , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Estadiamento de Neoplasias , Estudos Retrospectivos , Resultado do Tratamento , Adulto Jovem
9.
Prog. obstet. ginecol. (Ed. impr.) ; 54(10): 521-523, oct. 2011. ilus
Artigo em Espanhol | IBECS | ID: ibc-90962

RESUMO

Se presenta el caso clínico de una paciente de 39 años con absceso tuboovárico diagnosticado por RM pélvica. Destacamos la importancia de esta técnica de imagen para diferenciarlos de otros procesos pélvicos, principalmente neoplásicos (AU)


We present the case of a 39-year-old woman with a tubo-ovarian abscess diagnosed by pelvic magnetic resonance imaging. We highlight the importance of this imaging technique in differentiating these abscesses from other pelvic processes, especially neoplasms (AU)


Assuntos
Humanos , Feminino , Adulto , Espectroscopia de Ressonância Magnética , Espectroscopia de Ressonância Magnética/métodos , Imageamento por Ressonância Magnética , Abscesso/complicações , Abscesso/diagnóstico , Doença Inflamatória Pélvica/complicações , Doença Inflamatória Pélvica/diagnóstico , Dor Abdominal/etiologia , Escherichia coli/isolamento & purificação , Fatores de Risco , Abscesso , Doença Inflamatória Pélvica/fisiopatologia , Doença Inflamatória Pélvica , Ultrassonografia , Vagina/patologia , Vagina , Infecções por Escherichia coli
11.
Enferm Infecc Microbiol Clin ; 29(4): 313-4, 2011 Apr.
Artigo em Espanhol | MEDLINE | ID: mdl-21333395
14.
Prog. obstet. ginecol. (Ed. impr.) ; 54(1): 27-29, ene. 2011. ilus
Artigo em Espanhol | IBECS | ID: ibc-85771

RESUMO

Se presenta el caso clínico de una paciente de 39 años, con hidrosálpinx diagnosticado por resonancia magnética en el contexto de una enfermedad pélvica inflamatoria. Destacamos la importancia de esta técnica de imagen para diferenciarlo de otros procesos pélvicos, principalmente neoplásicos(AU)


We present the case of a 39 year old woman with hidrosálpinx diagnosed by pelvis magnetic resonance in the context of pelvic inflammatory disease. We note the importance of this imaging technique to differentiate it from other pelvic processes, especially neoplasms(AU)


Assuntos
Humanos , Feminino , Adulto , Doenças das Tubas Uterinas/patologia , Doenças das Tubas Uterinas , Tubas Uterinas/patologia , Tubas Uterinas , Imageamento por Ressonância Magnética , Doença Inflamatória Pélvica/diagnóstico , Doença Inflamatória Pélvica/patologia , Laparotomia , Doença Inflamatória Pélvica , Diabetes Mellitus Tipo 2/complicações , Abscesso/complicações , Abscesso/diagnóstico , Pelve/patologia , Pelve
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...